Skip to main content
. 2021 Dec 30;6(1):37–45. doi: 10.1182/bloodadvances.2021005056

Table 3.

Patient outcomes

Outcome Study population (n = 20)
Response at 1 mo
 Complete response 12 (60%)
 Partial response 3 (15%)
 Stable disease 3 (15%)
 Progressive disease 1 (5%)
 Unknown 1 (5%)
Best response
 Complete response 15 (75%)
 Partial response 1 (5%)
 Stable disease 1 (5%)
 Progressive disease 3 (15%)
Acute GVHD 17 (85%)
Chronic GVHD 9 (45%)
PFS, median, y 1.57 (95 CI, 0.22-6.94)
OS, median, y 6.45 (1.10 lower limit; upper limit does not exist)